The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling

Carcinogenesis

Volumn 36, Issue , 2015, Pages S38-S60

  Engström, Wilhelm ^a   Darbre, Philippa ^b   Eriksson, Staffan ^a   Gulliver, Linda ^c   Hultman, Tove ^a,b   Karamouzis, Michalis V ^d   Klaunig, James E ^e   Mehta, Rekha ^f   Moorwood, Kim ^g   Sanderson, Thomas ^h   Sone, Hideko ⁱ   Vadgama, Pankaj ^j   Wagemaker, Gerard ^k   Ward, Andrew ^g   Singh, Neetu ^l   Al Mulla, Fahd ^m   Al Temaimi, Rabeah ^m   Amedei, Amedeo ⁿ   Colacci, Anna Maria ^o   Vaccari, Monica ^o   Mondello, Chiara ^p   Ivana Scovassi, A ^p   Raju, Jayadev ^f   Hamid, Roslida A ^q   Memeo, Lorenzo ^r   Forte, Stefano ^r   Roy, Rabindra ^s   Woodrick, Jordan ^s   Salem, Hosni K ^t   Ryan, Elizabeth ^u   Brown, Dustin G ^u   Bisson, William H ^v   more..

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UNIVERSITY OF READING   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF ATHENS   (Greece)

^e INDIANA UNIVERSITY   (United States)

^f TOXICOLOGY RESEARCH DIVISION   (Canada)

^g UNIVERSITY OF BATH   (United Kingdom)

^h INRS INSTITUT ARMAND FRAPPIER   (Canada)

ⁱ NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k HACETTEPE UNIVERSITY   (Turkey)

^l KING GEORGE'S MEDICAL UNIVERSITY   (India)

^m KUWAIT UNIVERSITY   (Kuwait)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o Center for Environmental Carcinogenesis and Risk Assessment   (Italy)

^p CNR   (Italy)

^q UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^r Mediterranean Institute of Oncology   (Italy)

^s GEORGETOWN UNIVERSITY   (United States)

^t CAIRO UNIVERSITY   (Egypt)

^u Veterinary Dentistry and Oral Surgery   (United States)

^v OREGON STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CYTOKINE; CYTOSOL RECEPTOR; ENDOCRINE DISRUPTOR; ENVIRONMENTAL CHEMICAL; ESTROGEN; ESTROGEN RECEPTOR; GROWTH FACTOR; MEMBRANE RECEPTOR; NANOPARTICLE; DANGEROUS GOODS;

CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE REGULATION; CELL PROLIFERATION; CLASSIFICATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL PROTECTION; HUMAN; HYPOTHESIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; DRUG EFFECTS; NEOPLASMS;

ANIMALS; CARCINOGENS, ENVIRONMENTAL; CELL PROLIFERATION; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84937714253     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv030     Document Type: Review

References (286)

1. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
2. Hanahan, D. et al. (2011) Hallmarks of cancer. Cell, 144, 646-674.
3. Später, D. et al. (2014) How to make a cardiomyocyte. Development, 141, 4418-4431.
4. Baserga, R. (1985) The Biology of Cell Reproduction. Harvard University Press, Boston, MA.
5. Raff, M.C. (1992) Social controls on cell survival and cell death. Nature, 356, 397-400.
6. van Loo, P. et al. (2010) Allele specific copy number analysis of tumours. Proc. Natl Acad. Sci. USA, 107, 16910-16915.
7. Russnes, H.G. et al. (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci. Transl. Med., 2, 38ra47.
8. Holt, S. et al. (1986) In vitro thymidine labelling index in primary operable breast cancer. Eur. J. Surg. Oncol., 12, 53-57.
9. Elston, C.W. et al. (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19, 403-410.
10. Mitchison, J.M. (1971) The Biology of the Cell Cycle. Cambridge University Press, Cambridge, UK.
11. Zetterberg, A. et al. (1965) Quantitative cytophotometric and autoradiographic studies on the rate of protein synthesis during interphase in mouse fibroblasts in vitro. Exp. Cell Res., 40, 1-11.
12. Howard, A. et al. (1951) Synthesis of nucleoprotein in bean root cells. Nature, 167, 599-600.
13. Pardee, A.B. (1974) A restriction point for control of normal animal cell proliferation. Proc. Natl Acad. Sci. USA, 71, 1286-1290.
14. Zetterberg, A. et al. (1991) Coordination between cell growth and cell cycle transit in animal cells. Cold Spring Harb. Symp. Quant. Biol., 56, 137-147.
15. Larsson, O. et al. (1985) Cell-cycle-specific induction of quiescence achieved by limited inhibition of protein synthesis: counteractive effect of addition of purified growth factors. J. Cell Sci., 73, 375-387.
16. Larsson, O. et al. (1985) Consequences of parental exposure to serumfree medium for progeny cell division. J. Cell Sci., 75, 259-268.
17. Larsson, O. et al. (1986) Immediate effects of serum depletion on dissociation between growth in size and cell division in proliferating 3T3 cells. J. Cell. Physiol., 127, 267-273.
18. Hahn, W.C. et al. (1999) Creation of human tumour cells with defined genetic elements. Nature, 400, 464-468.
19. Westermarck, J. et al. (2008) Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med., 14, 152-160.
20. Sancar, A. et al. (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem., 73, 39-85.
21. Sherr, C.J. et al. (2002) The RB and p53 pathways in cancer. Cancer Cell, 2, 103-112.
22. Petritsch, C. et al. (2000) TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev., 14, 3093-3101.
23. Boehm, J.S. et al. (2005) Transformation of human and murine fibroblasts without viral oncoproteins. Mol. Cell. Biol., 25, 6464-6474.
24. Gille, H. et al. (1999) Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem., 274, 22033-22040.
25. Kerkhoff, E. et al. (1998) Cell cycle targets of Ras/Raf signalling. Oncogene, 17, 1457-1462.
26. Yuan, T.L. et al. (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene, 27, 5497-5510.
27. Manning, B.D. et al. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
28. Huang, J. et al. (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J., 412, 179-190.
29. Sun, Y. et al. (2008) Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc. Natl Acad. Sci. USA, 105, 8286-8291.
30. Toschi, A. et al. (2009) Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol. Cell. Biol., 29, 1411-1420.
31. Foster, D.A. (2009) Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim. Biophys. Acta, 1791, 949-955.
32. Guertin, D.A. et al. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
33. Ezhevsky, S.A. et al. (2001) Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol. Cell. Biol., 21, 4773-4784.
34. Harbour, J.W. et al. (1999) Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell, 98, 859-869.
35. Weinberg, R.A. (2007) pRb and control of the cell cycle clock. In The Biology of Cancer. Garland Science, New York, NY, pp. 255-307.
36. Ekholm, S.V. et al. (2001) Accumulation of cyclin E is not a prerequisite for passage through the restriction point. Mol. Cell. Biol., 21, 3256-3263.
37. Martinsson, H.S. et al. (2005) Single cell analysis of G1 check points- the relationship between the restriction point and phosphorylation of pRb. Exp. Cell Res., 305, 383-391.
38. Ho, A. et al. (2002) Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr. Opin. Genet. Dev., 12, 47-52.
39. Massagué, J. (2004) G1 cell-cycle control and cancer. Nature, 432, 298-306.
40. Donovan, J. et al. (2000) Transforming growth factor-β and breast cancer:cell cycle arrest by transforming growth factor-β and its disruption in cancer. Breast Cancer Res., 2, 116-124.
41. Dotto, G.P. et al. (1985) Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature, 318, 472-475.
42. Lu, Z. et al. (1997) Tumor promotion by depleting cells of protein kinase C delta. Mol. Cell. Biol., 17, 3418-3428.
43. Lu, Z. et al. (1998) Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell. Biol., 18, 839-845.
44. Zetterberg, A. et al. (1981) Glutamine and the regulation of DNA replication and cell multiplication in fibroblasts. J. Cell. Physiol., 108, 365-373.
45. Zetterberg, A. et al. (1995) What is the restriction point? Curr. Opin. Cell Biol., 7, 835-842.
46. Stiles, C.D. et al. (1979) Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc. Natl Acad. Sci. USA, 76, 1279-1283.
47. Glass, D.J. (2010) PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol., 346, 267-278.
48. Gwinn, D.M. et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell, 30, 214-226.
49. Foster, D.A. et al. (2010) Regulation of G1 cell cycle progression. Genes Cancer, 1, 1124-1131.
50. Yang, S. et al. (2004) During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. Pigment Cell Res., 17, 74-83.
51. Lee, C.J. et al. (2014) Targeting of magnolin on ERKs inhibits Ras/ERKs/ RSK2-signaling-mediated neoplastic cell transformation. Carcinogenesis, 35, 432-441.
52. Wieduwilt, M.J. et al. (2008) The epidermal growth factor receptor family:biology driving targeted therapeutics. Cell. Mol. Life Sci., 65, 1566-1584.
53. Karamouzis, M.V. et al. (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA, 298, 70-82.
54. Wang, Y.N. et al. (2010) Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene, 29, 3997-4006.
55. Lin, S.Y. et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol., 3, 802-808.
56. Zscheppang, K. et al. (2006) ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr. Pulmonol., 41, 1205-1212.
57. Karamouzis, M.C. et al. (2014) Tackling the cancer signal transduction "Labyrinth": a combinatorial use of biochemical tools with mathematical models will enhance the identification of optimal targets for each molecular defect. Tum Biol., 35, 5993-6002.
58. Parker, M.G. (1991) Nuclear Hormone Receptors: Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. Academic Press, London, UK, pp. 1-404.
59. Simons, S.S. et al. (2014) Dynamic structures of nuclear hormone receptors: new promises and challenges. Mol. Endocrinol., 28, 173-182.
60. White, J.O. et al. (1987) Activated oestrogen receptor in human breast cancer: clinical and biochemical correlates. Br. J. Surg., 74, 588-590.
61. Kuiper, G.G. et al. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA, 93, 5925-5930.
62. Webb, P. et al. (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol., 13, 1672-1685.
63. Safe, S. (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm., 62, 231-252.
64. Pearce, S.T. et al. (2004) The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol., 50, 3-22.
65. Ascenzi, P. et al. (2006) Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med., 27, 299-402.
66. Marino, M. et al. (2006) Estrogen signaling multiple pathways to impact gene transcription. Curr. Genom., 7, 497-508.
67. Lazennec, G. (2006) Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett., 231, 151-157.
68. Gulliver, L.S. et al. (2011) Novel approaches to quantify estradiolinduced loss of ERβ1 protein in older mouse ovarian surface epithelium:new tools to assess the role of ER protein subtypes in predisposing to ovarian epithelial cancer? Horm. Cancer, 2, 204-213.
69. Bardin, A. et al. (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer, 11, 537-551.
70. Bossard, C. et al. (2012) Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One, 7, e44787.
71. Paruthiyil, S. et al. (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res., 64, 423-428.
72. Anderson, E. et al. (2004) Steroid receptors and cell cycle in normal mammary epithelium. J. Mammary Gland Biol. Neoplasia, 9, 3-13.
73. Crabtree, J.S. et al. (2006) Development of a mouse model of mammary gland versus uterus tissue selectivity using estrogen- and progesterone- regulated gene markers. J. Steroid Biochem. Mol. Biol., 101, 11-21.
74. Fox, E.M. et al. (2008) Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol. Endocrinol., 22, 1781-1796.
75. Acconcia, F. et al. (2004) S-palmitoylation modulates human estrogen receptor-alpha functions. Biochem. Biophys. Res. Commun., 316, 878-883.
76. Tsai, C.L. et al. (2013) Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα). PLoS One, 8, e72999.
77. Wang, C. et al. (2014) Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling. Carcinogenesis., 35, 703-713.
78. Ruan, S.Q. et al. (2012) Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression. Mol. Med. Rep., 6, 131-138.
79. Nunes-Xavier, C.E. et al. (2013) Protein tyrosine phosphatases as novel targets in breast cancer therapy. Biochim. Biophys. Acta, 1836, 211-226.
80. Björnström, L. et al. (2002) Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol. Endocrinol., 16, 2202-2214.
81. Adams, B.D. et al. (2009) The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol. Endocrinol., 23, 1215-1230.
82. Pfeilschifter, J. et al. (2002) Changes in proinflammatory cytokine activity after menopause. Endocr. Rev., 23, 90-119.
83. Dinarello, C.A. et al. (1989) Interleukin-1 induced T-lymphocyte proliferation and its relation to IL-1 receptors. Adv. Exp. Med. Biol., 254, 45-53.
84. Dinarello, C.A. (2000) Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw., 11, 483-486.
85. Dong, C. et al. (2001) ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature, 409, 97-101.
86. Tato, C.M. et al. (2008) Alternative lifestyles of T cells. Nat. Immunol., 9, 1323-1325.
87. Wang, Y. et al. (2014) Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1. Mol. Cell. Endocrinol., 382, 791-803.
88. Hofmann, J.F. et al. (2001) G1-Cdk activity is required for both proliferation and viability of cytokine-dependent myeloid and erythroid cells. Oncogene, 20, 4198-4208.
89. Pignon, J.C. et al. (2009) Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res., 69, 2941-2949.
90. Eisermann, K. et al. (2013) Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol. Cancer, 12, 7.
91. Culig, Z. et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54, 5474-5478.
92. Migliaccio, A. et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J., 19, 5406-5417.
93. Migliaccio, A. et al. (2011) Analysis of androgen receptor rapid actions in cellular signaling pathways: receptor/Src association. Methods Mol. Biol., 776, 361-370.
94. Koivisto, P. et al. (1996) Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand. J. Clin. Lab. Invest. Suppl., 226, 57-63.
95. Visakorpi, T. et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9, 401-406.
96. Koivisto, P. et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57, 314-319.
97. Linja, M.J. et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 61, 3550-3555.
98. Veldscholte, J. et al. (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol., 41, 665-669.
99. Dehm, S.M. et al. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res., 68, 5469-5477.
100. Marcias, G. et al. (2010) Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum. Mutat., 31, 74-80.
101. Tepper, C.G. et al. (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res., 62, 6606-6614.
102. Gottlieb, B. et al. (2012) The androgen receptor gene mutations database:2012 update. Hum. Mutat., 33, 887-894.
103. Xu, Y. et al. (2006) Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin. Cancer Res., 12, 4072-4079.
104. Narashimamurthy, J. et al. (2004) Aromatase inhibitors: a new paradigm in breast cancer treatment. Curr. Med. Chem. Anticancer Agents, 4, 523-534.
105. Blanchard, Y. et al. (2007) The promoter of the rat 5alpha-reductase type 1 gene is bidirectional and Sp1-dependent. Mol. Cell. Endocrinol., 264, 171-183.
106. Sankpal, U.T. et al. (2011) Targeting Sp1 transcription factors in prostate cancer therapy. Med. Chem., 7, 518-525.
107. Chang, C.Y. et al. (2005) Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol. Sci., 26, 225-228.
108. Wang, L. et al. (2005) Androgen receptor corepressors: an overview. Prostate, 63, 117-130.
109. Powell, S.M. et al. (2006) Mechanisms of androgen receptor repression in prostate cancer. Biochem. Soc. Trans., 34(Pt 6), 1124-1127.
110. Feng, S. et al. (2013) Role of aryl hydrocarbon receptor in cancer. Biochim. Biophys. Acta, 1836, 197-210.
111. Yang, X. et al. (2005) The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene, 24, 7869-7881.
112. Rajapakse, N. et al. (2002) Combining xenoestrogens at levels below individual no-observed-effect concentrations dramatically enhances steroid hormone action. Environ. Health Perspect., 110, 917-921.
113. Silva, E. et al. (2002) Something from "nothing"-eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects. Environ. Sci. Technol., 36, 1751-1756.
114. Kortenkamp, A. (2007) Ten years of mixing cocktails: a review of combination effects of endocrine-disrupting chemicals. Environ. Health Perspect., 115, 98-105.
115. Charles, A.K. et al. (2013) Combinations of parabens at concentrations measured in human breast tissue can increase proliferation of MCF-7 human breast cancer cells. J. Appl. Toxicol., 33, 390-398.
116. Barr, L. et al. (2012) Measurement of paraben concentrations in human breast tissue at serial locations across the breast from axilla to sternum. J. Appl. Toxicol., 32, 219-232.
117. Darbre, P.D. (2012) Molecular mechanisms of oestrogen action on growth of human breast cancer cells in culture. Horm. Mol. Biol. Clin. Invest., 9, 65-85.
118. Russo, J. et al. (2006) The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol., 102, 89-96.
119. Bergman, A. et al. (2013) State of the Science of Endocrine Disrupting Chemicals. United Nations Environment Programme, World Health Organisation, Geneva.
120. Vandenberg, L.N. et al. (2012) Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr. Rev., 33, 378-455.
121. Pike, A.C. (2006) Lessons learnt from structural studies of the oestrogen receptor. Best Pract. Res. Clin. Endocrinol. Metab., 20, 1-14.
122. Darbre, P.D. (2006) Metalloestrogens: an emerging class of inorganic xenoestrogens with potential to add to the oestrogenic burden of the human breast. J. Appl. Toxicol., 26, 191-197.
123. Darbre, P.D. et al. (2010) Environmental oestrogens and breast cancer:evidence for combined involvement of dietary, household and cosmetic xenoestrogens. Anticancer Res., 30, 815-828.
124. Blair, R.M. et al. (2000) The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol. Sci., 54, 138-153.
125. Darbre, P.D. et al. (2013) Environmental oestrogens and breast cancer:long-term low-dose effects of mixtures of various chemical combinations. J. Epidemiol. Community Health, 67, 203-205.
126. Vanden Heuvel, J.P. (2007) The PPAR resource page. Biochim. Biophys. Acta, 1771, 1108-1112.
127. Barrera, C. et al. (2008) The role of PPAR ligands in controlling growthrelated gene expression and their interaction with lipoperoxidation products. PPAR Res., 2008, 524671.
128. Hasegawa, G. et al. (2012) Differential genotoxicity of chemical properties and particle size of rare metal and metal oxide nanoparticles. J. Appl. Toxicol., 32, 72-80.
129. Sweet, S. et al. (1995) Accumulation of human promyelocytic leukemic (HL-60) cells at two energetic cell cycle checkpoints. Cancer Res., 55, 5164-5167.
130. Ding, M. et al. (2009) Size-dependent effects of tungsten carbidecobalt particles on oxygen radical production and activation of cell signaling pathways in murine epidermal cells. Toxicol. Appl. Pharmacol., 241, 260-268.
131. Xu, A. et al. (2009) Genotoxic responses to titanium dioxide nanoparticles and fullerene in gpt delta transgenic MEF cells. Part. Fibre Toxicol., 6, 3.
132. AshaRani, P.V. et al. (2009) Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano, 3, 279-290.
133. Huang, X. et al. (2010) The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials, 31, 6142-6153.
134. Blaauboer, B.J. (2010) Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health. B Crit. Rev., 13, 242-252.
135. Rotroff, D.M. et al. (2010) Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci., 117, 348-358.
136. Wetmore, B.A. et al. (2012) Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci., 125, 157-174.
137. Wambaugh, J.F. et al. (2013) Dosimetric anchoring of in vivo and in vitro studies for perfluorooctanoate and perfluorooctanesulfonate. Toxicol. Sci., 136, 308-327.
138. Chang, X. et al. (2015) Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Appl. In Vitro Toxicol., 1, 33-44.
139. Zheng, W. et al. (2015) Altered glucose metabolism in Harvey-ras transformed MCF10A cells. Mol. Carcinog., 54, 111-120.
140. Guo, J.Y. et al. (2011) Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev., 25, 460-470.
141. Buganim, Y. et al. (2010) p53 regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res., 70, 2274-2284.
142. Lin, S. et al. (2012) Attenuation of TGF-β signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol. Biol. Cell, 23, 1569-1581.
143. Arbiser, J.L. et al. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl Acad. Sci. USA, 94, 861-866.
144. Dunn, K.L. et al. (2009) Increased genomic instability and altered chromosomal protein phosphorylation timing in HRAS-transformed mouse fibroblasts. Genes Chromosomes Cancer, 48, 397-409.
145. Ninomiya, Y. et al. (2004) K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res., 64, 2759-2765.
146. Choudhary, S. et al. (2007) Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Mol. Cancer Ther., 6, 1099-1111.
147. Di Micco, R. et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444, 638-642.
148. Koh, M. et al. (2015) Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Rasinduced epithelial to mesenchymal transition. Int. J. Cancer, 136, E508-E520.
149. Rimessi, A. et al. (2014) H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling. Oncogene, 33, 2329-2340.
150. de Launay, D. et al. (2010) Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis. Am. J. Pathol., 177, 3010-3024.
151. Wang, S.E. et al. (2010) Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene, 29, 3335-3348.
152. Alfonso Pecchio, A.R. et al. (2011) c-Fos activates and physically interacts with specific enzymes of the pathway of synthesis of polyphosphoinositides. Mol. Biol. Cell, 22, 4716-4725.
153. Przybyszewski, J. et al. (2010) Dietary energy restriction, in part through glucocorticoid hormones, mediates the impact of 12-O-tetradecanoylphorbol-13-acetate on jun D and fra-1 in Sencar mouse epidermis. Mol. Carcinog., 49, 592-602.
154. Schreiber, M. et al. (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev., 13, 607-619.
155. Guinea-Viniegra, J. et al. (2012) Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17. J. Clin. Invest., 122, 2898-2910.
156. Scherer, S.J. et al. (2000) p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J. Biol. Chem., 275, 37469-37473.
157. Nishitani, J. et al. (1999) Recruitment of the retinoblastoma protein to c-Jun enhances transcription activity mediated through the AP-1 binding site. J. Biol. Chem., 274, 5454-5461.
158. Saha, M.N. et al. (2012) Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One, 7, e30215.
159. Yuan, F. et al. (2013) Overexpressed DNA polymerase iota regulated by JNK/c-Jun contributes to hypermutagenesis in bladder cancer. PLoS One, 8, e69317.
160. Liebermann, D.A. et al. (1998) AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis. Int. J. Oncol., 12, 685-700.
161. Gandhi, V. et al. (1992) Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother. Pharmacol., 31, 11-17.
162. Alfonso-De Matte, M.Y. et al. (2002) Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res., 62, 4575-4578.
163. Takakura, M. et al. (2005) Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol. Cell. Biol., 25, 8037-8043.
164. Spector, M. et al. (2000) Activation of mitogen-activated protein kinases is required for alpha1-adrenergic agonist-induced cell scattering in transfected HepG2 cells. Exp. Cell Res., 258, 109-120.
165. Murakami, Y. et al. (2013) N-myc downstream-regulated gene 1 promotes tumor inflammatory angiogenesis through JNK activation and autocrine loop of interleukin-1α by human gastric cancer cells. J. Biol. Chem., 288, 25025-25037.
166. Ono, M. (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci., 99, 1501-1506.
167. Ranjan, P. et al. (2006) Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. Antioxid. Redox Signal., 8, 1447-1459.
168. Rossmeislová, L. et al. (2013) Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes, 62, 1990-1995.
169. Huffman, D.M. et al. (2013) Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc(1638N/+) female mice. Cancer Prev. Res. (Phila.), 6, 177-187.
170. Pedersen, L. et al. (2012) Muscle-derived expression of the chemokine CXCL1 attenuates diet-induced obesity and improves fatty acid oxidation in the muscle. Am. J. Physiol. Endocrinol. Metab., 302, E831-E840.
171. De Larco, J.E. et al. (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin. Cancer Res., 10, 4895-4900.
172. Vaites, L.P. et al. (2013) ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis. Oncogene, 33, 129-133.
173. Shen, X.H. et al. (2013) Interleukin-8 prevents oxidative stressinduced human endothelial cell senescence via telomerase activation. Int. Immunopharmacol., 16, 261-267.
174. Medina, R.J. et al. (2013) Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function. Stem Cells, 31, 1657-1668.
175. Li, S. et al. (2012) TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol., 10, 73.
176. Lau, M.Y. et al. (2013) Association of cyclin D and estrogen receptor α36 with hepatocellular adenomas of female mice under chronic endoplasmic reticulum stress. J. Gastroenterol. Hepatol., 28, 576-583.
177. Stumpf, C. et al. (2013) Anti-inflammatory effects of danshen on human vascular endothelial cells in culture. Am. J. Chin. Med., 41, 1065-1077.
178. Avena, P. et al. (2013) Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis. Cell Cycle, 12, 1360-1370.
179. Xin, X. et al. (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem., 274, 9116-9121.
180. Lu, M. et al. (2005) Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J. Biol. Chem., 280, 6742-6751.
181. Masamune, A. et al. (2002) Ligands of peroxisome proliferator-activated receptor-gamma induce apoptosis in AR42J cells. Pancreas, 24, 130-138.
182. Wang, J. et al. (2006) Ceramide induces apoptosis via a peroxisome proliferator-activated receptor gamma-dependent pathway. Apoptosis, 11, 2043-2052.
183. Gizard, F. et al. (2008) The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycledependent telomerase activation. Circ. Res., 103, 1155-1163.
184. Chang, H.J. et al. (2013) Peroxisome proliferator-activated receptor γ agonist suppresses human telomerase reverse transcriptase expression and aromatase activity in eutopic endometrial stromal cells from endometriosis. Clin. Exp. Reprod. Med., 40, 67-75.
185. Cheung, K.F. et al. (2013) CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth. Cancer, 119, 1217-1226.
186. Liu, H. et al. (2003) PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res. Treat., 79, 63-74.
187. Gelman, L. et al. (1999) An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci., 55, 932-943.
188. Pillai, R. et al. (2011) Aryl hydrocarbon receptor nuclear translocator/ hypoxia-inducible factor-1{beta} plays a critical role in maintaining glucose-stimulated anaplerosis and insulin release from pancreatic {beta}-cells. J. Biol. Chem., 286, 1014-1024.
189. Roman, A.C. et al. (2009) Dioxin receptor deficiency impairs angiogenesis by a mechanism involving VEGF-A depletion in the endothelium and transforming growth factor-beta overexpression in the stroma. J. Biol. Chem., 284, 25135-25148.
190. Fan, Y. et al. (2010) The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res., 70, 212-220.
191. Caruso, J.A. et al. (2006) Aryl hydrocarbon receptor modulation of tumor necrosis factor-alpha-induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8-independent. J. Biol. Chem., 281, 10954-10967.
192. O'Donnell, E.F. et al. (2014) The aryl hydrocarbon receptor mediates raloxifene induced apoptosis in estrogen receptor negative hepatoma and breast cancer cells. Cell Death Dis., 5, e1038.
193. Park, K.T. et al. (2005) The aryl hydrocarbon receptor predisposes hepatocytes to Fas-mediated apoptosis. Mol. Pharmacol., 67, 612-622.
194. Korkalainen, M. et al. (2012) Dioxin induces genomic instability in mouse embryonic fibroblasts. PLoS One, 7, e37895.
195. Sarkar, P. et al. (2006) Activation of telomerase in BeWo cells by estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin in co-operation with c-Myc. Int. J. Oncol., 28, 43-51.
196. Ray, S. et al. (2009) Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: a tumor promoting event? Biochem. Pharmacol., 77, 681-688.
197. Pontillo, C.A. et al. (2013) Action of hexachlorobenzene on tumor growth and metastasis in different experimental models. Toxicol. Appl. Pharmacol., 268, 331-342.
198. Zhang, S. et al. (2012) Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol. Cancer Ther., 11, 108-118.
199. Fallahi, P. et al. (2012) Cytokines and HCV-related disorders. Clin. Dev. Immunol., 2012, 468107.
200. Mimeault, M. et al. (2013) Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol. Aspects Med., 39, 3-22.
201. van Cruijsen, H. et al. (2005) Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int. J. Cancer, 117, 883-888.
202. Rimawi, M.F. et al. (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 116, 1234-1242.
203. Rush, J.S. et al. (2012) Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J. Biol. Chem., 287, 712-722.
204. Ying, W.Z. et al. (2007) EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. J. Am. Soc. Nephrol., 18, 131-142.
205. Heeg, S. et al. (2011) EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis. Cancer Sci., 102, 351-360.
206. Breindel, J.L. et al. (2013) EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res., 73, 5053-5065.
207. Fletcher, E.V. et al. (2013) EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Mol. Cancer Res., 11, 1574-1584.
208. Martins, A.D. et al. (2013) Control of Sertoli cell metabolism by sex steroid hormones is mediated through modulation in glycolysisrelated transporters and enzymes. Cell Tissue Res., 354, 861-868.
209. Lin, C. et al. (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell, 139, 1069-1083.
210. Tuttle, R. et al. (2012) Novel senescence associated gene, YPEL3, is repressed by estrogen in ER+ mammary tumor cells and required for tamoxifen-induced cellular senescence. Int. J. Cancer, 130, 2291-2299.
211. Liu, S. et al. (2010) Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Mol. Cancer Ther., 9, 2016-2025.
212. Kim, S.H. et al. (2010) Androgen receptor interacts with telomeric proteins in prostate cancer cells. J. Biol. Chem., 285, 10472-10476.
213. Mirochnik, Y. et al. (2012) Androgen receptor drives cellular senescence. PLoS One, 7, e31052.
214. Cheng, W.L. et al. (2011) Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann. Oncol., 22, 2267-2276.
215. McKay, L.I. et al. (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev., 20, 435-459.
216. Hayashi, S. et al. (2008) Estrogen signalling in cancer microenvironment and prediction of response to hormonal therapy. J. Steroid Biochem. Mol. Biol., 109, 201-206.
217. Grubisha, M.J. et al. (2013) Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment. Steroids, 78, 538-541.
218. Schults, M.A. et al. (2014) Hypoxia diminishes the detoxification of the environmental mutagen benzo[a]pyrene. Mutagenesis, 29, 481-487.
219. Severson, P.L. et al. (2014) Exome-wide mutation profile in benzo[a] pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 775-776, 48-54.
220. Li, Z.D. et al. (2007) Benzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1alpha degradation. Biochem. Biophys. Res. Commun., 357, 517-523.
221. Zhao, P. et al. (2010) Comparative proteomic analysis of anti-benzo(a) pyrene-7,8-dihydrodiol-9,10-epoxide-transformed and normal human bronchial epithelial G0/G1 cells. Chem. Biol. Interact., 186, 166-173.
222. Kuang, D. et al. (2013) Dose-response relationships of polycyclic aromatic hydrocarbons exposure and oxidative damage to DNA and lipid in coke oven workers. Environ. Sci. Technol., 47, 7446-7456.
223. Chen, W. et al. (2012) Low-dose gamma-irradiation inhibits IL-6 secretion from human lung fibroblasts that promotes bronchial epithelial cell transformation by cigarette-smoke carcinogen. Carcinogenesis, 33, 1368-1374.
224. Li, W. et al. (2013) Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells. Cancer Sci., 104, 143-148.
225. Kaur, J. et al. (2008) Chemopreventive activity of lantadenes on twostage carcinogenesis model in Swiss albino mice: AP-1 (c-jun), NFkappaB (p65) and P53 expression by ELISA and immunohistochemical localization. Mol. Cell. Biochem., 314, 1-8.
226. Mukherjee, J.J. et al. (2006) Attenuation of BPDE-induced p53 accumulation by TPA is associated with a decrease in stability and phosphorylation of p53 and downregulation of NFkappaB activation: role of p38 MAP kinase. Carcinogenesis, 27, 631-638.
227. Mason, S.A. et al. (2010) The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest. New Drugs, 28, 575-586.
228. Xiao, L. et al. (2008) Phorbol ester-induced apoptosis and senescence in cancer cell models. Methods Enzymol., 446, 123-139.
229. Shimao, Y. et al. (1999) TPA-enhanced motility and invasion in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: selective role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC downregulation and antisense oligonucleotides treatment. Clin. Exp. Metastasis, 17, 351-360.
230. Arimoto-Kobayashi, S. et al. (2013) Chemopreventive effects of the juice of Vitis coignetiae Pulliat on two-stage mouse skin carcinogenesis. Nutr. Cancer, 65, 440-450.
231. Rahman, S. et al. (2011) Nordihydroguaiaretic acid from creosote bush (Larrea tridentata) mitigates 12-O-tetradecanoylphorbol-13-acetateinduced inflammatory and oxidative stress responses of tumor promotion cascade in mouse skin. Evid. Based Complement. Alternat. Med., 2011, 734785.
232. Priya, S. et al. (2013) Dysregulation of pathways involved in the processing of cancer and microenvironment information in MCA + TPA transformed C3H/10T1/2 cells. In Vitro Cell. Dev. Biol. Anim., 49, 295-305.
233. Jiang, Y. et al. (2013) Prenatal exposure to bisphenol A at the reference dose impairs mitochondria in the heart of neonatal rats. J. Appl. Toxicol., 34, 1012-1022.
234. Lee, H.S. et al. (2012) Set, a putative oncogene, as a biomarker for prenatal exposure to bisphenol A. Asian Pac. J. Cancer Prev., 13, 2711-2715.
235. Dairkee, S.H. et al. (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis, 34, 703-712.
236. Durando, M. et al. (2011) Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J. Steroid Biochem. Mol. Biol., 127, 35-43.
237. Allard, P. et al. (2010) Bisphenol A impairs the double-strand break repair machinery in the germline and causes chromosome abnormalities. Proc. Natl Acad. Sci. USA, 107, 20405-20410.
238. Terasaka, H. et al. (2005) Cytotoxicity and apoptosis-inducing activity of bisphenol A and hydroquinone in HL-60 cells. Anticancer Res., 25(3B), 2241-2247.
239. Xu, J. et al. (2002) Bisphenol A induces apoptosis and G2-to-M arrest of ovarian granulosa cells. Biochem. Biophys. Res. Commun., 292, 456-462.
240. Goodson, W.H. III et al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis, 32, 1724-1733.
241. Takahashi, A. et al. (2004) Bisphenol A from dental polycarbonate crown upregulates the expression of hTERT. J. Biomed. Mater. Res. B Appl. Biomater., 71, 214-221.
242. Zhu, H. et al. (2010) Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Oncol. Rep., 23, 129-139.
243. Feng, Y. et al. (2012) Bisphenol AF may cause testosterone reduction by directly affecting testis function in adult male rats. Toxicol. Lett., 211, 201-209.
244. Zhang, Y.H. et al. (2013) Mechanism of perfluorooctanesulfonate (PFOS)-induced apoptosis in the immunocyte. J. Immunotoxicol., 10, 49-58.
245. Qian, Y. et al. (2010) Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. J. Toxicol. Environ. Health A, 73, 819-836.
246. Eriksen, K.T. et al. (2010) Genotoxic potential of the perfluorinated chemicals PFOA, PFOS, PFBS, PFNA and PFHxA in human HepG2 cells. Mutat. Res., 700, 39-43.
247. Wang, X. et al. (2013) PFOS-induced apoptosis through mitochondrion- dependent pathway in human-hamster hybrid cells. Mutat. Res., 754, 51-57.
248. Lee, Y.J. et al. (2013) Perfluorooctane sulfonate-induced apoptosis of cerebellar granule cells is mediated by ERK 1/2 pathway. Chemosphere, 90, 1597-1602.
249. Mollenhauer, M.A. et al. (2011) Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng., 46, 97-108.
250. Bonnefoy, A. et al. (2012) Environmental nitration processes enhance the mutagenic potency of aromatic compounds. Environ. Toxicol., 27, 321-331.
251. Klaunig, J.E. et al. (2003) PPARalpha agonist-induced rodent tumors:modes of action and human relevance. Crit. Rev. Toxicol., 33, 655-780.
252. Butler, E.G. et al. (1988) Induction of hepatic peroxisome proliferation in mice by lactofen, a diphenyl ether herbicide. Toxicol. Appl. Pharmacol., 93, 72-80.
253. Nakagawa, Y. et al. (1995) Cytotoxic effects of postharvest fungicides, ortho-phenylphenol, thiabendazole and imazalil, on isolated rat hepatocytes. Life Sci., 57, 1433-1440.
254. Kleinstreuer, N.C. et al. (2011) Environmental impact on vascular development predicted by high-throughput screening. Environ. Health Perspect., 119, 1596-1603.
255. Sişman, T. et al. (2010) Toxicologic evaluation of imazalil with particular reference to genotoxic and teratogenic potentials. Toxicol. Ind. Health, 26, 641-648.
256. Lee, J.A. et al. (2011) The effect of ketamine with remifentanil for improving the quality of anaesthesia and recovery in paediatric patients undergoing middle-ear ventilation tube insertion. J. Int. Med. Res., 39, 2239-2246.
257. Allard, P. et al. (2013) A C. elegans screening platform for the rapid assessment of chemical disruption of germline function. Environ. Health Perspect., 121, 717-724.
258. Altuntas, I. et al. (2003) Role of reactive oxygen species in organophosphate insecticide phosalone toxicity in erythrocytes in vitro. Toxicol. In Vitro, 17, 153-157.
259. Takashima, A. et al. (2013) Targeting the RAS oncogene. Expert Opin. Ther. Targets, 17, 507-531.
260. Baird, W.M. et al. (2005) Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ. Mol. Mutagen., 45, 106-114.
261. Loomis, D. et al. (2013) The carcinogenicity of air pollution. Lancet Oncol., 14, 1262-1263.
262. Vaccari, M. et al. (2015) Identification of pathway based toxicity in the Balb/c 3T3 cell model. Toxicol. In Vitro., in press.
263. Jarvis, I.W. et al. (2014) Nanomolar levels of PAHs in extracts from urban air induce MAPK signaling in HepG2 cells. Toxicol. Lett., 229, 25-32.
264. Khan, G.A. et al. (2005) Harvey-ras gene expression and epidermal cell proliferation in dibenzo[a,l]pyrene-treated early preneoplastic SENCAR mouse skin. J. Invest. Dermatol., 125, 567-574.
265. Culp, S.J. et al. (2000) DNA adduct measurements, cell proliferation and tumor mutation induction in relation to tumor formation in B6C3F1 mice fed coal tar or benzo[a]pyrene. Carcinogenesis, 21, 1433-1440.
266. Crews, D. et al. (2014) Nature, nurture and epigenetics. Mol. Cell. Endocrinol., 398, 42-52.
267. Ho, S.M. et al. (2012) Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J., 53, 289-305.
268. Pogribny, I.P. (2010) Epigenetic events in tumorigenesis: putting the pieces together. Exp. Oncol., 32, 132-136.
269. Koturbash, I. et al. (2011) Role of epigenetic events in chemical carcinogenesis- a justification for incorporating epigenetic evaluations in cancer risk assessment. Toxicol. Mech. Methods, 21, 289-297.
270. Pogribny, I.P. et al. (2013) Environmental toxicants, epigenetics, and cancer. Adv. Exp. Med. Biol., 754, 215-232.
271. Coyle, J.T. (2006) Glial metabolites of tryptophan and excitotoxicity:coming unglued. Exp. Neurol., 197, 4-7.
272. IARC (2014) IARC Monograph. Vol. 106. IARC, p. 97.
273. Cohn, P.D. et al. (1994) Assessing human health effects from chemical contaminants in drinking water. New Jersey Med., 91, 719-722.
274. Fagliano, J. et al. (1990) Drinking water contamination and the incidence of leukemia: an ecologic study. Am. J. Public Health, 80, 1209-1212.
275. Wild, C.B. (2005) Complementing the genome with an exposome. The outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomarkers Prev., 14, 1847-1850.
276. Secky, L. et al. (2013) The sulfatase pathway for estrogen formation:targets for the treatment and diagnosis of hormone-associated tumors. J. Drug Deliv., 2013, 957605.
277. Gulliver, L.S. et al. (2012) Repeat estradiol exposure differentially regulates protein expression patterns for estrogen receptor and E-cadherin in older mouse ovarian surface epithelium: implications for replacement and adjuvant hormone therapies? Steroids, 77, 674-685.
278. Gulliver Linda, S.M. (2015) Estradiol synthesis and metabolism and risk of ovarian cancer in older women taking prescribed or plantderived estrogen supplementation. J Steroids Hormone Res., in press.
279. Zetterberg, A. et al. (1982) Growth activation of resting cells: induction of balanced and imbalanced growth. Ann. N.Y. Acad. Sci., 397, 130-147.
280. Zetterberg, A. et al. (1984) The relative effects of different types of growth factors on DNA replication, mitosis, and cellular enlargement. Cytometry, 5, 368-375.
281. Ekström, W. et al. (1992) Growth at the cellular level. Acta Ped. Scand., 377, 35-39.
282. Engström, W. et al. (1983) Phosphate and the requirements for DNA replication in normal and virus transformed 3T3 cells. Biochemical J., 214, 695-702
283. Granérus, M. et al. (1996) Growth factors and apoptosis. Cell Prolif., 29, 309-314.
284. Halje, M. et al. (2012) Review: the effect of insulin-like growth factor II in the regulation of tumour cell growth in vitro and tumourigenesis in vivo. In Vivo, 26, 519-526.
285. Bergman, D. et al. IGF in development and disease. Gerontology, 59, 240-249.
286. Qiao, M. et al. (2014) The pursuit of oncotargets through understanding defective cell cycle regulation. Oncotarget 1, 544-551.